drugset
Drugs / IZALONTAMAB
last change 29 days ago re-read 9 days ago

IZALONTAMAB

also known as SI-B001 · Her3 x egfr si-b001

Monoclonal antibody targets EGFR, ERBB3

Developed for
head and neck squamous cell carcinoma · non-small cell lung carcinoma · colorectal cancer · esophageal squamous cell carcinoma · lung adenocarcinoma · squamous cell lung carcinoma
Investigated by
Sichuan Baili Pharmaceutical Co., Ltd. · Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. · SystImmune Inc.

Trials 11

today NCT06668961 · Ph 2 NCT05949606 · Ph 1/2 NCT05943795 · Ph 3 NCT05668858 · Ph 1/2 NCT05020769 · Ph 2/3 NCT05054439 · Ph 2 NCT05022654 · Ph 2 NCT05020457 · Ph 2 NCT05039944 · Ph 2 NCT05044897 · Ph 2 NCT04603287 · Ph 1
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04603287 Apr 2020 → Dec 2025 overdue — Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05949606 Oct 2023 → Dec 2026 expected non-small cell lung carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT05668858 Feb 2023 → Dec 2026 expected head and neck squamous cell carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 26 trials
Phase 2 NCT06668961 Nov 2024 → Nov 2026 expected head and neck squamous cell carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT05054439 Dec 2021 → Dec 2026 expected head and neck squamous cell carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT05022654 Dec 2021 → Dec 2025 overdue esophageal squamous cell carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT05020457 Dec 2021 → Dec 2025 overdue non-small cell lung carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 2 NCT05039944 Nov 2021 → Jun 2022 colorectal cancer Sichuan Baili Pharmaceutical Co., Ltd. Terminated No outcome recorded Stop: Business
Phase 2 NCT05044897 Oct 2021 → Dec 2025 overdue head and neck squamous cell carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT05020769 Jan 2022 → Dec 2025 overdue non-small cell lung carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT05943795 Jul 2023 → Jul 2026 overdue lung adenocarcinoma, squamous cell lung carcinoma Sichuan Baili Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2023-10-09 Sichuan Biokin Pharmaceutical Co., Ltd. Regulatory 四川百利天恒药业股份有限公司自愿披露关于SI-B001（EGFR×HER3双特异性抗体）联合多西他赛项目临床试验申请获得FDA批准的公告 cninfo.com.cn ↗

All press releases naming this drug 11 releases

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as IZALONTAMAB ChEMBL registry synonym — accepted as the source's own label CHEMBL5095384 ↗
Known as Her3 x egfr si-b001 ChEMBL registry synonym — accepted as the source's own label CHEMBL5095384 ↗
Known as SI-B001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603287 ↗
10

NCT06668961 ↗

NCT05044897 ↗

NCT05020457 ↗

NCT05943795 ↗

NCT05668858 ↗

NCT05949606 ↗

NCT05020769 ↗

NCT05039944 ↗

NCT05054439 ↗

NCT05022654 ↗
Modality Monoclonal antibody “SI-B001, an EGFR/HER3 Bispecific Antibody” NCT04603287 ↗
Route Intravenous “Administration by intravenous infusion.” NCT04603287 ↗
Target EGFR “SI-B001, an EGFR/HER3 Bispecific Antibody” NCT04603287 ↗